Introduction
============

Retinal neurons are considered to be a part of the central nervous system (CNS). As a consequence, they share several properties with CNS neurons, including the inability to undergo spontaneous regeneration in response to damage. Since there is no possibility to replace cells that become non-functional due to damage or aging, these long-living cells are likely endowed with specific mechanisms to protect them from both intracellular and environmental stress ([@B109]). Retinal neurons, including retinal ganglion cells (RGCs), are exposed to similar stressors as observed in other cell types, i.e., UV radiation, high temperature, ischemia, hypo- or hyperoxic conditions, harmful microbes, allergens and environmental pollutants, all factors able to induce reactive oxygen species (ROS) production and/or release ([@B34]). In addition, retinal neurons are exposed to the glutamate, which in excess concentration is a neuron-specific toxin. Subsequently, ROS production results in genes expression alteration, protein misfolding and other events leading to cell stress with apoptosis as the terminal process. Since the technologies allowing CNS repair by cell replacement are still under development, the efficiency of the endogenous cellular protective systems is a key factor for neuronal apoptotic susceptibility and survival ([@B19]; [@B260]). As a consequence of this, the neurodegeneration can be described as an imbalance between protective and damaging factors affecting RGCs (Figure [1](#F1){ref-type="fig"}).

![Schematic diagram illustrating the impact of endogenous neuroprotective mechanisms on RGC rescue after injury. ^∗^If factors representing the endogenous rescue-mechanisms are sufficiently activated they can allow functional recovery of RGCs; however, if these mechanisms are not efficient enough, irreversible cell death may occur.](fnins-12-00834-g001){#F1}

Retinal ganglion cells projections form the optic nerve (ON) and conduct the visual signal from the retina to visual centers in the brain (i.e., lateral geniculate nuclei). RGCs are the site of numerous primary retinal and optic nerve pathologies among which glaucoma, ischemic optic neuropathy and Leber's hereditary optic neuropathy (LHON) are the most common. Moreover, there are pathologies with ocular signs, such as diabetes ([@B87]; [@B254]), Alzheimer's disease (AD) ([@B106]) and brain tumors ([@B250]). Damage to RGCs or the ON results in impairment of visual signal propagation and subsequent progressive visual field defects. Since the retina represents a highly organized structure, with neighboring cells closely interacting with each other, death of a single RGC can induce self-perpetuating processes affecting survival of surrounding cells; these detrimental events are related mostly to the release of intracellular glutamate from the dying cells that triggers an excitotoxic cascade ([@B40]). Therefore, impairment of RGC endogenous neuroprotective mechanisms and increased RGC apoptosis can participate in spreading of pro-death signals resulting in progressive damage to the retinal cells.

Endogenous neuroprotective mechanisms in neurons, including RGCs, can be classified in various categories. Neurotrophic factors and both enzymatic and non-enzymatic mechanisms of ROS scavenging are well-known players in RGC homeostasis. In addition, systems of misfolded protein degradation (i.e., autophagy) and mechanisms controlling gene expression are gaining increasing attention and represent potentially interesting targets for therapy and/or prevention of neurodegeneration. Here, we summarize and describe the most recently studied endogenous neuroprotective factors involved in RGC survival, which include (a) neurotrophic/growth factors (neuronal, vascular, or both), (b) processes regulating the redox status, and (c) other factors, including pathways regulating apoptosis/cell death and neuroinflammation modulators (Figure [1](#F1){ref-type="fig"}).

Neurotrophic/Growth Factors (Neuronal, Vascular or Both)
========================================================

Neurotrophic Factors
--------------------

Neurotrophic factors regulate the development and survival of neurons. They seem to be involved in the endogenous neuroprotection of RGCs. A variety of studies have reported that neurotrophic factors, particularly nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), glial cell-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF), protect RGCs in various models of ON injuries ([@B126]; [@B61]; [@B103]; Table [1](#T1){ref-type="table"}). In agreement with their well-known role in maintaining neuronal homeostasis, neurotrophic factors have been proposed as novel therapies for various neurodegenerative diseases, however, outcomes of known clinical trials were not satisfactory, presenting only partial or no expected effects ([@B96]; [@B7]; [@B231]). Interestingly, some CNS pathologies, such as AD, Parkinson disease and Huntington disease, display ocular signs and alterations within RGCs ([@B23]; [@B207]); thus, for these neurodegenerative diseases, neurotrophic factors promoting the survival of neurons may be of beneficial at both the central and ocular levels.

###### 

Expression of neurotrophins and their receptors in different RGC degeneration models and human glaucoma (↑ upregulation; ↓ downregulation).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factor      Model                                                        Observation                                             Methods Used to Analyze         Reference
  ----------- ------------------------------------------------------------ ------------------------------------------------------- ------------------------------- ------------------
  **BDNF**    **MOUSE**                                                                                                                                            

                                                                                                                                                                   

              Microbeads injection                                         ONH:\                                                   Western blotting, ELISA         [@B103], [@B102]
                                                                           5 months -- nsa\                                                                        
                                                                           1 year -- ↓ BDNF (WT \< BDNF^-/+^)                                                      

              NMDA-induced retinal degeneration                            14 and 21 days -- ↓ BDNF                                IHC                             [@B123]

              Model of spontaneous glaucoma (DBA/2J)                       With age -- ↓ BDNF, ↓ TrkB                              Western blotting                [@B47]

                                                                                                                                                                   

              **RAT**                                                                                                                                              

                                                                                                                                                                   

              Episcleral cauterization                                     Retina:\                                                Western blotting, IHC, RT-PCR   [@B214]
                                                                           28 days -- ↑ BDNF, ↑ mRNA BDNF; TrkB -- nsa; ↑ p75                                      

              Retinal ischemia (acute IOP elevation)                       RGC:\                                                   IHC                             [@B200]
                                                                           4 h -- ↑ BDNF\                                                                          
                                                                           RGC and ONH:\                                                                           
                                                                           4 h -- ↑ Trk B                                                                          

              Hypertonic saline episcleral injections into aqueous veins   ONH:\                                                   IHC                             [@B125]
                                                                           7 days -- ↓ BDNF\                                                                       
                                                                           14 days -- ↑ BDNF (glia)\                                                               
                                                                           Retina:\                                                                                
                                                                           7 and 14 days -- ↓ BDNF\                                                                
                                                                           \>14 days -- ↑ BDNF (RGC soma)                                                          

              Carotid artery occlusion                                     Retina:\                                                Western blotting, IHC, ELISA    [@B99]
                                                                           3 and 14 days -- ↓ BDNF mRNA\                                                           
                                                                           3 days -- ↑ BDNF\                                                                       
                                                                           14 and 60 days -- ↓ BDNF (GCL)\                                                         
                                                                           3, 14, and 60 days -- ↓TrkB (GCL)                                                       

                                                                                                                                                                   

              **HUMAN**                                                                                                                                            

                                                                                                                                                                   

              Tissues from fresh post-mortem glaucoma subjects             ONH:\                                                   Western blotting, ELISA         [@B103], [@B102]
                                                                           ↓ BDNF                                                                                  

                                                                                                                                                                   

  **NGF**     **RAT**                                                                                                                                              

                                                                                                                                                                   

              Episcleral cauterization                                     Retina:\                                                Western blotting, IHC, RT-PCR   [@B214]
                                                                           7 days -- ↑ NGF (transient); ↑ Trk A                                                    

              Hypertonic saline injection                                  35 days -- ↑NGF; ↑ NGF mRNA; ↑TrkA; ↑p75                ELISA, RT-PCR, IHC              [@B48]

              Carotid artery occlusion                                     Retina:\                                                Western blotting, IHC, ELISA    [@B99]
                                                                           3 and 14 days -- ↓NGF mRNA\                                                             
                                                                           3 and 14 days -- ↓TrkA                                                                  

                                                                                                                                                                   

              **HUMAN**                                                                                                                                            

                                                                                                                                                                   

              POAG                                                         Serum:\                                                 ELISA                           [@B191]
                                                                           early and moderate glaucoma -- ↓ NGF\                                                   
                                                                           advanced glaucoma -- nsa                                                                

                                                                                                                                                                   

  **CNTF**    **MOUSE**                                                                                                                                            

                                                                                                                                                                   

              NMDA-induced retinal degeneration                            14 and 21 days -- ↑CNTF                                 IHC                             [@B123]

                                                                                                                                                                   

              **RAT**                                                                                                                                              

                                                                                                                                                                   

              Carotid artery occlusion                                     Retina:\                                                Western blotting, IHC, ELISA    [@B99]
                                                                           3 and 14 days -- ↑CNTF mRNA                                                             

              Laser photocoagulation                                       14 days -- ↑CNTF                                        IHC, Immunoblot                 [@B121]

                                                                                                                                                                   

              **HUMAN**                                                                                                                                            

                                                                                                                                                                   

              POAG                                                         Lacrimal fluid -- ↓CNTF\                                ELISA                           [@B230]
                                                                           Aqueous humor -- ↓CNTF                                                                  

                                                                                                                                                                   

  **GDNF**    **MOUSE**                                                                                                                                            

                                                                                                                                                                   

              NMDA-induced retinal degeneration                            14 and 21 days -- ↑GDNF                                 IHC                             [@B123]

                                                                                                                                                                   

              **RAT**                                                                                                                                              

                                                                                                                                                                   

              Carotid artery occlusion                                     Retina:\                                                Western blotting, IHC, ELISA    [@B99]
                                                                           3 and 14 days -- ↓GDNF mRNA                                                             

                                                                                                                                                                   

  **NT4/5**   **RAT**                                                                                                                                              

                                                                                                                                                                   

              Hypertonic saline episcleral injections into aqueous veins   ONH:\                                                   IHC                             [@B125]
                                                                           7 days -- ↓ NT4/5\                                                                      
                                                                           14 days -- ↑ NT4/5 (glia)\                                                              
                                                                           Retina:\                                                                                
                                                                           7 and 14 days -- ↓ NT4/5\                                                               
                                                                           \>14 days -- ↑ NT4/5 (RGC soma)                                                         

                                                                                                                                                                   

  **NT-3**    **RAT**                                                                                                                                              

                                                                                                                                                                   

              Episcleral cauterization                                     Retina:\                                                Western blotting, IHC, PCR      [@B214]
                                                                           28 days -- nsa; ↑ Trk C (Müller cells but not in RGC)                                   

              Carotid artery occlusion                                     3 and 14 days -- ↓ NT-3 mRNA\                           Western blotting, IHC, ELISA    [@B99]
                                                                           3 and 14 days -- ↓ TrkC                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

nsa, no significant alterations; RGC, retinal ganglion cells; GCL, ganglion cell layer; ONH, optic nerve head; POAG, primary open-angle glaucoma; BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; CNTF, ciliary neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; NT-4/5, neurotrophin-4/5; NT-3, neurotrophin-3; Trk A/B/C, the tropomyosin kinase receptor A/B/C; IHC, immunohistochemistry; RT-PCR, reverse transcription

\-

polymerase chain reaction.

Neurotrophins can bind to different receptors and transduce diverse intracellular signals, finally leading to opposite outcomes -- death or survival. For instance, the binding of a neurotrophin to the tyrosine-receptor kinase (Trk) promotes cell survival, whereas interaction with p75 NT receptors (p75NTR) induces apoptosis ([@B136]; Figure [2](#F2){ref-type="fig"}).

![Neurotrophic factor (NTFs) signaling pathways. Brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) bind to two families of receptors. Tropomyosin kinase (Trk) receptor binds with high affinity to promote cell survival via phospholipase C-γ (PLC-γ), phosphoinositide-3 kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways (light blue arrows). Binding of NTFs to low affinity p75 receptor activates cell death through the JNK pathway (light blue and red arrows). Ciliary neurotrophic factor (CNTF) binding to CNTFRα receptor and two subunits -- gp130 and leukemia inhibitory factor (LIFRβ) activate the Janus kinase/signal transducer and activator of transcription (JAK/STAT) (blue-violet arrows), MAPK and PI3K pathways (dark blue arrows). Binding of glial cell line-derived neurotrophic factor (GDNF) to the GDNFα receptor and tyrosine kinase RET receptor stimulates PLC-γ, MAPK and PI3K pathways (green arrows). Akt controls the activities of several proteins important in promoting cell survival, including substrates that directly regulate the caspase cascade, such as BAD. Phosphorylated BAD prevents its proapoptotic actions ([@B232]) (red arrows). The pathway illustration was based on Reactome (<https://reactome.org/> PMID: 29145629, PMID: 29077811). Represents the pathways responsible for endogenous cell-rescue mechanisms in glaucoma; these pathways were significantly activated when IOP was elevated, but decreased to baseline levels when IOP was lowered ([@B150]; [@B149]).](fnins-12-00834-g002){#F2}

### Brain-Derived Neurotrophic Factor (BDNF)

Neurotrophin deprivation, mainly BDNF, is considered as one of the leading causes of RGC death in glaucoma. BDNF is synthesized in the superior colliculus and the lateral geniculate nucleus and retrogradely transported to the RGC bodies. Moreover, this neurotrophic factor is produced locally in RGCs ([@B111]). Exposure to high IOP induces a two-phase response (a decrease followed by an increase) in BDNF and NT4/5 expression in RGCs and in the ON head glia, suggesting the participation of these neurotrophins in endogenous neuroprotective responses of RGCs ([@B252]; [@B125]; Table [1](#T1){ref-type="table"}). It is widely accepted that BDNF upregulation is an early response in RGCs that undergo axonal injury ([@B136]). Several studies indicated that the therapeutic effects of different neuroprotective agents in promoting RGC survival are related to their induction of retinal BDNF expression ([@B18]; [@B202]; [@B47]). Our previous studies also confirm these results. Application of extracts from pre-degenerated peripheral nerves stimulate RGC survival through induction of endogenous retinal BDNF expression in glaucoma ([@B202]). It is important to note that BDNF levels in the serum and tears of glaucoma patients are significantly lower than in control subjects, suggesting that deficits in this neurotrophin may participate in RGC death in glaucoma ([@B89], [@B88]; [@B191]). Furthermore, BDNF inhibits the osmotic swelling of Müller cells and bipolar cells ([@B30]) and upregulates the glutamate/aspartate transporter (GLAST) and Glutamine Synthetase (GS) expression in Müller cells in the mouse retina, increasing glutamate uptake during hypoxia ([@B53]). To our knowledge, no clinical trials evaluating the potential therapeutic effects of BDNF in glaucoma have been conducted so far, however, there have been many attempts and future plans in developing BDNF-based therapies.

### Nerve Growth Factor (NGF)

Nerve growth factor is another important growth factor affecting the survival of nerve cells. NGF deprivation can lead to apoptosis preceded by impairment of glucose uptake, an increase in ROS production, activation of c-Jun N-terminal kinase (JNK) and its downstream target c-Jun, and caspase activation ([@B79]; [@B161]). Mature NGF (mNGF) is derived from its precursor form (proNGF) after conversion by a protease cascade within the extracellular space ([@B36]). It has been suggested that disturbance in proNGF to mNGF turnover can be involved in neurodegeneration, such as AD, as well as seizures, and cerebral ischemia ([@B67]; [@B36]). NGF is produced and utilized by RGCs, bipolar cells and glial cells ([@B210]) and can be involved in neuroplasticity of neurons in the visual cortex and geniculate nucleus ([@B164]). Several studies indicate that NGF protects RGCs after ON ischemia or transection, ocular hypertension and glaucoma ([@B49]; [@B210]; [@B8]; [@B43]). The downregulation of NGF and NGF-receptor expression in the retina and ON is reduced by ocular application of NGF in a rat model of glaucoma and protects animals from neurodegeneration ([@B49]). Moreover, NGF, similarly to BDNF, prevents the osmotic swelling of rat Müller glia, by a double action: directly, by activating autocrine/paracrine FGF signaling, and indirectly, by inhibiting the swelling of bipolar cells through induction of cytokine release from Müller cells. The inhibitory effect is mediated by activation of TrkA but not p75NTR ([@B84]). The binding of NGF to TrkA in RGCs promotes their survival, while the binding of NGF to p75NTR is mainly responsible for pro-apoptotic responses (Figure [2](#F2){ref-type="fig"}); however, the binding of NGF to both TrkA and p75NTR at the same time leads to RGC survival, since p75NTR acts in concert with TrkA-helping receptor ([@B255]). In the context of potential application of NGF in glaucoma, the safety of an 8-week treatment with 180 μg/ml recombinant human NGF (rhNGF) eye drop solution was tested in a masked, randomized, vehicle-controlled, phase Ib trial of 60 participants with chronic POAG (NCT02855450); for now, the conclusions of this study have not yet been published (Table [2](#T2){ref-type="table"} and Figure [3](#F3){ref-type="fig"}).

###### 

Glaucoma neuroprotective drug development pipeline.

  Agent                           Administration          Agent mechanism class                Mechanism of action                        [ClinicalTrials.gov](https://clinicaltrials.gov/) identifier   Phase/Status                 Sponsor                              Start date
  ------------------------------- ----------------------- ------------------------------------ ------------------------------------------ -------------------------------------------------------------- ---------------------------- ------------------------------------ ---------------
  rhNGF                           Eye drops               Neurotrophic factors                 Pro-survival/ neuroprotection              NCT02855450                                                    Ib/Recruiting                Dompé Farmaceutici S.p.A.            December 2016
  NT-501 (CNTF-secreting cells)   Implant                 Cell therapy/ neurotrophic factors   Pro-survival/ neuroprotection              NCT02862938                                                    II/Recruiting                Stanford University                  June 2016
  Ginkgo biloba extract           Oral                    Antioxidant/ neuroprotection         Antioxidant/ improving ocular blood flow   NCT02376114                                                    II                           Maisonneuve-Rosemont Hospital        August 2011
  GlaucoHealth^1^                 Oral                    Antioxidant/ neuroprotection         Antioxidant/Anti-inflammatory              NCT02984813                                                    I/Active, not recruiting     The New York Eye and Ear Infirmary   April 2016
  BMSC                            Intraocular injection   Stem cells                           Replacement of damaged cells               NCT03011541                                                    Not applicable/ Recruiting   MD Stem Cells                        January 2016
  BMSC                            Intraocular injection   Stem cells                           Replacement of damaged cells               NCT01920867                                                    Not applicable/ recruiting   MD Stem Cells                        August 2013
  BMSC                            Intraocular injection   Stem cells                           Replacement of damaged cells               NCT02330978                                                    I/Recruiting                 University of Sao Paulo              January 2014
  ADRC                            Intraocular injection   Stem cells                           Replacement of damaged cells               NCT02144103                                                    II/Recruiting                Kremlin Hospital^2^                  May 2014
  ANX007                          Intraocular injection   Other (biological -- antibody)       C1q inhibition                             NCT03488550                                                    I/Recruiting                 Annexon, Inc.                        March 2018

There are 1,287 interventions/treatments registered in

ClinicalTrials.gov

for glaucoma (accessed May 31, 2018), of which 9 agents may exert direct neuroprotective effects on the retina and/or optic nerve. See the text for further details on the classes.

1

Alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract.

2

Central Clinical Hospital w/Outpatient Health Centre of Business Administration for the President of Russian Federation. rhNGF, recombinant human NGF; BMSC, autologous bone marrow-derived stem cells; ADRC, adipose-derived regenerative cells.

![Major clinical trials for optic neuropathy therapeutics, including glaucoma.](fnins-12-00834-g003){#F3}

### Glial Cell Line-Derived Neurotrophic Factor (GDNF)

Glial cell line-derived neurotrophic factor is secreted by glial cells and binds to the GDNF-α receptor and tyrosine kinase RET receptor (Figure [2](#F2){ref-type="fig"}). RET is expressed in the inner nuclear layer and ganglion cell layer of the mammalian retina, whereas GDNF-α is expressed in RGCs, Müller glia, and amacrine cells ([@B272]; [@B6]). GDNF promotes axonal regeneration in the CNS and prevents apoptosis through the phosphoinositide-3 kinase (PI3K), mitogen-activated protein kinase (MAPK) and Src kinase pathways ([@B6]; Figure [2](#F2){ref-type="fig"}). GDNF upregulates GLAST in Müller glia and may indirectly protect RGCs by enhancing glutamate uptake ([@B139]). It has been suggested that GLAST impairment may be involved in the pathogenesis of glaucoma ([@B136]). To our knowledge, no clinical trials evaluating the potential therapeutic effects of GDNF in glaucoma have been conducted so far.

### Ciliary Neurotrophic Factor (CNTF)

Ciliary neurotrophic factor binds to CNTFRα receptors and two signal transducing transmembrane subunits -- gp130 and leukemia inhibitory factor (LIFR). This complex activates Janus kinase/signal transducer and activator of transcription (JAK/STAT), mitogen-activated protein kinase (MAPK)/ERK, and PI3/Akt signaling pathways ([@B136]; Figure [2](#F2){ref-type="fig"}). CNTF is expressed in the neural retina, retinal pigmented epithelium and ON head ([@B28]; [@B160]). The neurotrophic properties of CNTF were tested in several animal models of retinal diseases ([@B200]; [@B209]; [@B170]) and are currently under evaluation in clinical trials ([@B245]; [@B133]; [@B33], [@B32]; [@B44]). It has been suggested that the neuroprotective effects of this factor are mediated especially by Müller cells that directly respond to CNTF by releasing other neurotrophic factors such as bFGF ([@B263]). Furthermore, CNTF increases secretion of NT3 and decreases VEGF, IL8, and TGFb2 levels in primary cultures of human fetal retinal pigmented epithelial cells ([@B154]). After glaucoma induction, endogenous CNTF levels are elevated for up to 2 weeks, providing the transient activation of STAT3, which is important for antiapoptotic signaling (Table [1](#T1){ref-type="table"}). Thus, this endogenous neurotrophic response is not sufficient to protect the injured RGC. However, administration of exogenous CNTF significantly extends the activation time of STAT3 ([@B121]). The CNTF concentration is decreased in the aqueous humor, lacrimal fluid and blood serum in patients with primary open--angle glaucoma (POAG); interestingly, the lowest levels of this neurotrophic factor positively correlate with a more advanced state of the disease ([@B230]; Table [1](#T1){ref-type="table"}). Interestingly, the NT-501 ECT (encapsulated cell therapy) implant, a device containing a genetically modified CNTF-secreting cell line, is under evaluation in 60 POAG patients enrolled in an ongoing randomized, sham controlled, masked phase II clinical study (NCT02862938) ([@B248]; [@B21]; Table [2](#T2){ref-type="table"} and Figure [3](#F3){ref-type="fig"}).

Vascular Endothelial Growth Factor A (VEGF-A)
---------------------------------------------

Vascular endothelial growth factor A belongs to a superfamily including VEGF-B, -C, -D, and placental growth factor (PLGF). Among these members, the VEGF-A family is the most potent inducer of new vessel formation; more specifically, the pro-angiogenic VEGF~165~a isoform has a prominent role in neovascularization, and vessels permeability-related eye diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR) ([@B70]; [@B20]; [@B11]). Beside the effects on vasculature, the subject of a large number of research studies and reviews, VEGF-A, in particular the VEGF~121~ and VEGF~165~ isoforms, also exhibits neurotrophic and neuroprotective activities. It has been reported that in normal conditions, VEGF~165~b is the predominant isoform in human eye tissues and fluids; it is downregulated in the vitreous fluid of DR patients, where a switch in VEGF splicing from anti- to pro-angiogenic isoforms (from VEGF~165~b to VEGF~165~a) seems to occur ([@B77]). As with the pro-angiogenic VEGF~165~a, the anti-angiogenic VEGF~165~b exerts neuroprotective effects through VEGFR-2, p44/42 MAPK activation, and caspase-3 inhibition, but unlike VEGF~165~a, it does not involve either p38 MAPK or PI3K ([@B279]; [@B25]). Interestingly, VEGF endogenous expression has been confirmed in RGCs and amacrine cells in the human retina, where it participates in RGC neuroprotection mechanisms ([@B68]; [@B219]; [@B25]; [@B77]). This evidence suggests that pan-VEGF agents, although rapidly and effectively inhibiting neovascularization, vascular leakage, and other pathological changes in AMD or DR patients, exert detrimental effects in the long-term due to a loss of VEGF physiology at the ocular level ([@B11]; [@B86]; [@B75]). Importantly, anti-VEGF therapies primarily targeting neovascularization result in thinning of RNFL and lack VEGF-A-mediated neuroprotection ([@B35]; [@B162]; [@B147]; [@B148]).

Endogenous Growth Hormone
-------------------------

Growth hormone (GH) is a mitogenic peptide synthetized and released by somatotrophic cells in the pituitary gland. In addition, GH can be synthetized and released by neurons within the CNS, where it participates in stress-response and neuroprotection ([@B169]). In the human retina, GH and GH receptors (GHR) are expressed in RGCs, where the existence of RGC autocrine regulation by GH has been hypothesized ([@B220], [@B221]; [@B108]). In their study, [@B220] demonstrated that following retinal insults, apoptotic RGCs coincided with GH-negative cells, while GH-expressing RGCs survived longer times. Further investigations in chick embryos led to the conclusion that GH neuroprotection is likely ascribed to anti-apoptotic effects mediated by tyrosine kinase receptors, Akt phosphorylation, *Bax* gene regulation and caspase-3 inhibition ([@B220]).

Factors Regulating the Redox Status
===================================

Oxidative Stress Defense
------------------------

In recent years, oxidative stress and mitochondrial dysfunction have been indicated as potential causes of glaucomatous neurodegeneration. In this multi-factorial disease, both the anterior and posterior segments of the eye, specifically the trabecular meshwork (TM)/endothelium and the inner retina/RGC, can be affected by oxidative damage, finally leading to visual pathway alteration in a series of closely linked events that needs to be fully elucidated. An increasing body of evidence suggests that the phenomena occurring in the anterior chamber, such as the oxidative stress-induced functional alterations of the TM, lead to defects in the posterior segment and are considered as the background of the pathogenesis of glaucoma -- particularly, but not exclusively, high-tension glaucoma ([@B217]). In glaucoma, the cellular and molecular mechanisms leading to cell death in the TM and RGCs show high similarities; cell loss is the consequence of apoptosis triggered by oxidative stress ([@B217]). The maintenance of a balance between oxidative species production and clearance is particularly critical for the eye's health. Oxidative stress occurs when concentrations of ROS rise above physiologic range with no adequate increase in the activity and/or levels of antioxidant defenses, what leads to damage of cellular components (proteins, nucleic acids, and lipids) by oxidation and eventually to cell degeneration/loss ([@B104]). In physiologic conditions, various antioxidant and detoxifying factors at the ocular level, act in concert removing effectively ROS; however, harmful stimuli can lead to changes/malfunctioning in one or more antioxidant defense systems, what affects the global redox balance and finally contributes to pathological conditions. As already mentioned for neurotrophins, several lines of evidence indicate that the protein levels and enzymatic activities of antioxidant defenses in the aqueous humor (AH) are significantly altered in glaucoma. It was shown that global antioxidant potential level in the AH of glaucoma patients was lower than the mean of control cataract group ([@B72]), suggesting that a chronic exposure to ROS contributes in glaucoma to the progressive loss of TM cellularity and subsequent change of redox balance ([@B9]). At the systemic level, patients with POAG presented decreased total plasma antioxidant capacity compared to healthy subjects ([@B4]), what is in agreement with previous findings of [@B65] in the serum of patients with POAG and pseudoexfoliative glaucoma (PEG). Contrary, primary angle closure glaucoma (PACG) patients and control subjects showed comparable total serum antioxidant levels ([@B2]).

Endogenous Antioxidant Factors
------------------------------

Among antioxidants and detoxifying factors, glutathione (GSH) and the enzymes in the GSH pathway (GSH peroxidase, reductase, and transferase), superoxide dismutase (SOD), and catalase, are the most studied in relation to RGCs.

Glutathione is a low-molecular weight detoxifying molecule present in all mammalian tissues. In its reduced state, GSH is considered the master free radical scavenger, especially at the mitochondrial level, being used by GSH peroxidase (GPx) to inactivate hydrogen peroxide. This reaction leads to the formation of oxidized GSH, or GSSG; new GSH can be restored by GSH reductase in the presence of NADPH. GSH can also be conjugated to harmful xenobiotic substances by GSH transferase (GST), with the aim of detoxification. Blood GSH levels inversely correlate with aging in healthy subjects but not in glaucoma patients; however, independently of age, glaucoma patients displayed lower GSH content than the healthy individuals ([@B91]).

SOD converts the highly cytotoxic superoxide anion into hydrogen peroxide, and it is present in all eye structures. Three human SOD isoforms (the cytosolic Cu-ZnSOD, also named SOD1; the mitochondrial MnSOD, or SOD2; and the extracellular EC-SOD, or SOD3) have been detected in AH ([@B27]). In this fluid, decreased expression of SOD1/2 as well as of GST were observed in glaucoma patients in comparison to cataract control group ([@B17]). Conversely in serum, higher SOD1/2 levels were reported in glaucoma patients than controls ([@B65]). Increased SOD, as well as GPx activity, has been found in AH of glaucoma patients compared to cataract patients ([@B72]; [@B95]), as a possible compensating response to higher ROS levels. More recently, impairment in total serum SOD activity was detected in the glaucoma group, displaying specifically lower MnSOD levels than controls ([@B212]). In this study, glaucoma patients presented with a rise in the total oxidative status but not in the total antioxidant capacity.

Catalase (CAT) brakes hydrogen peroxide to water and oxygen. Some studies aimed to evaluate CAT in either AH or serum, or both, reported no significant differences in this enzyme (either levels or activity) between glaucoma and control subjects ([@B72]; [@B90]; [@B95]), while others demonstrated an impairment in CAT in glaucoma ([@B165]). A significant heterogeneity in the methods used to detect enzymatic activity can be found among the literature studies. Some of them measured the "total" enzymatic activity of the SOD family, others the activity of the specific isoforms (e.g., SOD1 and SOD2). In addition, the diversity of glaucoma types evaluated in these studies might be an additional source of variability and a critical point for the interpretation of the findings. A recent reviews and meta-analysis provide a more homogeneous picture of the local and systemic alterations in glaucoma patients, revealed an overall increase in oxidative stress markers in chronic glaucoma, in both the serum and the AH. Despite a general decrease in antioxidant markers in the serum, SOD and GPx increased in the AH, likely as a protective response in the eye against oxidative stress ([@B29]). A compensatory increase in SOD and GPx activity in association with increased oxidative processes was also found in the brains of the mouse model for glaucoma ([@B71]), supporting idea about the close link and mutual influence existing between the eye and brain.

In general, discrepancies between expression level and enzymatic activity are not infrequent, and they are not limited to compensatory mechanisms, where the decreased activity of a given enzyme (due to an age-related impairment of the biological system or any more specific cause) may be counterbalanced by an increase in its expression. Likewise, high concentration of an enzyme does not necessarily mean high activity. Gene polymorphisms of antioxidant enzymes may indeed be responsible for changes in their activity, possibly resulting in consecutive effects of glaucoma-induced oxidative damage.

The most common and best studied SNP of *SOD2* is the rs4880 allele. The rs4880 (C47T) (C) and (T) alleles give rise to either alanine (Ala) or valine (Val), respectively, at codon 16, located within the mitochondrial targeting sequence of SOD. There are conflicts in the literature over the effect of this SNP. Val (T) was associated with a less efficient transport of SOD2 in the mitochondria and a lower enzyme activity compared to Ala (C) ([@B241]; [@B249]). However, in another study on healthy human erythrocytes isolated from Asian or Caucasian volunteers, SOD2 activity was 33% higher in (T;T) or (C;T) individuals compared to (C;C) subjects ([@B22]). The same authors reported significant variation of allele frequencies between ethnicities; SOD2 enzyme activity was also shown to be higher (+15%) in females than males. The differences between the lowest and highest levels of medium enzymatic activity were relevant not only for SOD2 but also for GSx and CAT (56-fold, 6-fold, and 8-fold, respectively). We can conclude that antioxidant enzyme activities show a high inter-individual variability that may be related to genetic polymorphisms and that gender and ethnicity probably contribute to discrepancies among the various studies. The possible role of the C47T SOD2 mutation in normal-tension glaucoma pathogenesis was investigated in a German population and no association was found ([@B267]). Similar findings were obtained in Saudi patients with POAG; however, on the basis of the study results, the authors suggested that the C47T SOD2 mutation can be a risk factor for various clinical indices, such as high IOP and severe clinical course ([@B3]). The possible link between SOD1 35A/C and the risk of POAG was studied in a Polish population and no association was found ([@B167]). The same study found instead that the C/T genotype of both GPx Pro198 Leu and CAT -262C/T confers major risks to developing POAG.

Antioxidant Therapies for RGC Degeneration
------------------------------------------

Based on these studies, several antioxidant agents, as well as molecules indirectly affecting factors/pathways related to redox response (such as those blocking glutamate excitotoxicity-induced oxidative stress), have been shown to provide RGC protection in *in vivo* models, and may be of interest for glaucoma treatment and/or prevention ([@B235]; [@B190]). The authors are aware that changes of the endogenous antioxidant factor levels may represent only one of the protective effects, and that other underlying molecular mechanisms may be responsible of the RGC loss prevention provided by these agents; however, a thorough discussion and critical interpretation of the cited evidence are beyond the scope of this review.

It was reported that retinal GSH decreases due to ischemia/reperfusion (I/R) injury were counteracted by subcutaneous Vitamin E treatment in guinea pigs ([@B16]); similarly, subcutaneous administration of Vitamin E, as well as carotenoid derivative -- Lutein, reversed the decreased GSH levels in rat retinas with I/R injuries ([@B59]). GSH decrease in the retinas of glaucomatous mice was prevented by oral administration of alpha-Luminol GVT^®^, a compound endowed with antioxidant and anti-inflammatory properties ([@B92]). In rat retinas with I/R injury, intraperitoneal injection of Methane increased both the antioxidant enzyme activities (SOD, CAT, GPx) and anti-apoptotic gene (*Bcl2*) expression, ultimately decreasing RGC loss, total retinal layer thinning, and visual dysfunction ([@B159]). Intraperitoneal injection of Crocin, a pharmacologically active component of *Crocus sativus L.* (saffron), increased GSH levels and total SOD activity, decreased ROS and counteracted RGC loss in I/R injury ([@B42]). It was also reported that a diet supplemented with alpha-lipoic acid (ALA), either alone ([@B117]) or in association with SOD ([@B184]), was able to protect RGCs in the presence of ocular ischemic and pressure stress. Transgenic SOD1-overexpressing mice showed accelerated RGCs death after ON injury and showed an enhancement of RGC survival when systemically injected with alpha2-adrenoreceptor agonist brimonidine ([@B151]). In animal models of rat glaucoma and rabbit retinal NMDA excitotoxicity, it has been demonstrated that brimonidine provides neuroprotection by modulating NMDA receptor function through postsynaptic alpha2-adrenoreceptors in RGCs; the alpha2-mediated brimonidine effect leads to a reduction of intracellular cAMP production, the latter being responsible for NMDA activation in RGCs ([@B62]). *In vivo* evidence confirmed that topical treatment with brimonidine decreased retinal damage induced by ocular hypertension and showed that analogous results were obtained by intraperitoneal administration of N-acetyl cysteine ([@B195]). Brimonidine was compared to timolol in the Low-pressure Glaucoma Treatment Study -- LoGTS -- with the aim of evaluating if either treatment protected the optic nerve and prevented vision loss in adults ([@B224]). After 4 years, the brimonidine group showed less progressive loss of the visual field than the timolol group; however, since many people dropped out of the study, especially from the brimonidine group, and the authors did not report data for visual acuity, the interpretation of the results was difficult and evidence of the real effectiveness of brimonidine as a neuroprotective agent in glaucoma was not provided.

In the panorama of gene therapy, intravitreal, adeno-associated. virus-mediated pretreatment with SOD2 attenuated oxidative stress and reduced mitochondrial dysfunction in RGCs and the ON in glaucoma ([@B122]). In comparison with wild-type counterparts, RGC survival and up-regulation of antioxidant enzymes (such as SOD2, CAT, GPx), were observed in I/R retinas of mice overexpressing Frataxin, a mitochondrial protein serving important functions in iron homeostasis and oxidative stress responses ([@B222]). Protection of RGCs was also obtained in a mouse model of partial ON-crush following oral administration of Persimmon leave (*Diospyros kaki*) extract; this extract rich in several bioactive compounds, exerts antioxidant and pro-survival activities by modulating the expression of defensive and apoptotic genes (by increasing SOD1, GST, GPx; or by decreasing PPAR, p53, respectively) ([@B216]). Oral administration of Ginkgo biloba extract seems to provide beneficial effects on RGCs in a glaucoma animal model ([@B114]) and to ameliorate pre-existing visual field damage in some patients with normal-tension glaucoma ([@B206]; [@B146]). However, [@B98] did not show a statistically significant difference in visual field outcomes after Ginkgo biloba supplementation in Chinese patients. These conflicting reports suggest that racial differences may also play an important role ([@B131]). In addition to antioxidant properties, Ginkgo biloba increases blood flow through vasodilation and reduces blood viscosity ([@B131]). The safety and efficacy of a combination of antioxidants and anti-inflammatory agents in OAG patients are currently under evaluation in a phase I clinical trial (NCT02984813) (Table [2](#T2){ref-type="table"}).

*In vivo* evidence of neuroprotection, mainly in favor of RGCs, have been reported for other antioxidant/antiapoptotic agents, such as *Lycium Barbarum Lynn* extracts ([@B39]), Stanniocalcin-1 ([@B135]), Oryzanol ([@B196]), Resveratrol and Riluzole, tested either alone or in combination in glaucoma models ([@B158]; [@B203]). Interestingly, evidence in a mouse model of normal-tension glaucoma showed that caloric restriction promotes retinal cell survival by increasing the expression of CAT and neurotrophic factors and by reducing global oxidative stress ([@B97]). Another antioxidant -- taurine protects cells against oxidative stress by upregulating enzymes such as thioredoxin reductase, glutathione peroxidase and SOD. It is suggested that a decrease in retinal blood perfusion in glaucoma may reduce taurine uptake and cause degeneration of RGCs ([@B276]; [@B80], [@B81]).

It is important to have different therapeutic approaches to counteract glaucoma progression, for instance some drugs currently used to control the disease, such as timolol and dorzolamide, display antioxidant properties, possibly contributing to their therapeutic effects ([@B118]; [@B218]). Pronounced oxidative stress is a feature of mitochondrial optic neuropathies, including LHON ([@B168]). In this group of inherited diseases, a genetic defect within RGC mitochondrial proteins results in a functional problems in mitochondrial oxidative phosphorylation and subsequent decrease of energetic substrates availability leads to RGC degeneration ([@B37]). Supplementation of coenzyme Q~10~ analog idebenone enables electron transfer through complex I-III of the mitochondrial respiratory chain, reduces ROS production and energy disbalance and provides sufficient neuroprotection and RGC recovery in certain groups of LHON patients ([@B63]; [@B278]). It is worth mentioning that two phase IV clinical trials on idebenone (Raxone^®^) in LHON patients started in 2016 and are currently ongoing (NCT02774005).

NF-E2-Related Factor 2 (Nrf2)
-----------------------------

In the constellation of novel potential neuroprotective therapies, the modulation of expression of enzymes/proteins/factors may be a strategy to increase antioxidant defenses. In this regard, many antioxidant and detoxifying enzymes, such as GST, SOD, are regulated by neuroprotective NF-E2-related factor 2 (Nrf2), a transcription factor activated by oxidative stress and electrophilic molecules and whose relevance in many ocular diseases including glaucoma has been recently reviewed ([@B24]). Nrf2 deficiency is characterized by increased oxidative stress and neuronal degeneration and aggravates RGC loss in animals subjected to either ON damage ([@B112]) or I/R injury ([@B260]).

Interestingly, among *in vivo* evidence for potential neuroprotective agents, the Nrf2 activator triterpenoid 1-(2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl) imidazole (CDDO-Im) reduced ON crush-induced RGC death in mice by upregulating the expression of antioxidant and phase II detoxifying enzymes ([@B112]). Similar findings were reported for CDDO-Im in mice subjected to I/R ([@B271]). Treatment with Trimetazidine, an anti-ischemic drug and metabolic modulator endowed with neuroprotective properties, attenuated retinal damage and RGC death in an acute glaucoma animal model by activating the Nrf2-pathway ([@B254]), further suggesting that pharmacologic induction of the Nrf2-pathway may represent a novel neuroprotective tool in retinal diseases. In agreement, the Nrf2 modulator monomethyl fumarate, the biologically active metabolite of dimethyl fumarate, displayed neuroprotective effects and decreased neuronal cell loss in the ganglion cell layer of mouse retinas after I/R injuries ([@B46]). New achievements in gene therapy allowed to spatio-temporal regulation of Nrf2 expression by specifically targeting RGCs at risk of degeneration in murine ON injury, thus preventing death of stressed cells and limiting undesired off-target effects on healthy neurons ([@B83]).

Factors and Pathways Regulating Apoptosis/Cell Death and Neuroinflammation
==========================================================================

P53
---

One of the important regulatory proteins involved in apoptosis of RGCs is the tumor suppressor protein p53. This protein is a transcription factor which upregulates the expression of the proapoptotic gene *Bax* and downregulates the expression of the antiapoptotic gene *Bcl2* ([@B54]; [@B69]). It is suggested that *p53* gene polymorphisms may be involved in POAG pathogenesis. It has been shown that the properties of p53 change depending on the residue occupying position 72 in the peptide chain. In particular, the codon 72 polymorphism involves a proline (Pro) to arginine (Arg) amino acid substitution at position 72 (Pro72Arg). The Arg72 isoform more efficiently induces apoptosis, while Pro72 shows greater ability to arrest the cell cycle in response to DNA damage ([@B156]; [@B183]; [@B93]). However, some of the abovementioned studies concerning the association between the codon 72 polymorphism and POAG are in disagreement, suggesting that ethnic differences may affect genetic predisposition to this disease ([@B183]; [@B93]). In particular, some evidence indicates that the p53 codon 72 polymorphism may be associated with increased risk of POAG in Asian but not in Caucasian populations ([@B100]; [@B183]; [@B93]), while others have not confirmed these results ([@B163]). Furthermore, some reports suggest that the Arg72Pro polymorphism of the *TP53* gene may be related to progression of POAG rather than with risk of occurrence of this disease ([@B188]).

Heat Shock Proteins
-------------------

Heat shock proteins (Hsp) represent a family of proteins playing the role of molecular chaperones -- regulating proper macromolecule turnover in the cytosol ([@B116]). Hsp are involved in oxidative stress defense, inhibition of proinflammatory cytokines and inhibition of apoptotic pathways. They supervise protein folding and unfolding, as well as degradation of irreparably misfolded proteins ([@B237]; [@B129]; [@B76]; [@B130]). Regarding RGCs, the function of Hsp70 and Hsp27 are the most widely documented ([@B45]; [@B204]). Induction of Hsp can inhibit apoptosis both directly -- via suppression of proapoptotic factors, i.e., p53 and a wide range of Bcl2 family members, including Bax, Bid, Akt and Apaf-1, -- and indirectly -- by suppressing proinflammatory cytokines, i.e., IL17, IL1β, TNFα, or IL-8 and inhibiting oxidative stress ([@B119]; [@B208]; [@B242]). Fatal cellular effects of oxidative stress alleviated by Hsp include repair of misfolded proteins, prevention of protein aggregation, and reduction of ROS-dependent genotoxicity ([@B119]; [@B171]). In humans, *Hsp70* gene polymorphism is related to a higher risk of POAG development, confirming the relevance of this Hsp in endogenous neuroprotection of RGCs ([@B187]).

The BCL-2 Family
----------------

A major role in the apoptotic process of RGCs during glaucoma is played by members of the BCL-2 family. In glaucoma, the decreased expression of the pro-survival bcl-2 and bcl-xl genes is accompanied by an increase in pro-apoptotic bax and bad gene expression. The proapoptotic BCL-2 family of proteins promotes the release of cytochrome c from the mitochondrial intermembrane space into the cytoplasm. Cytochrome c binding to apoptosis inducing factor-1 (Apaf-1) and procaspase-9 activates caspase-9 and then caspase-3 and -7 causing apoptosis. Bcl-2 inhibits this pathway by blocking the activation of bax and bak ([@B149]; [@B85]). Overexpression of bcl-2 prevents RGC loss in a rat axotomy model ([@B141]; [@B166]). Moreover, changes in expression of transcription factors such as immediate early genes (IEGs) which regulate the transcription of bax and bcl-2 genes, are observed in various experimental glaucoma models and the changes in the expression of these genes can be associated with both RGC apoptosis and survival ([@B143]; [@B150]; [@B149]). In addition, overexpression of bcl-2 leads to an increase in the cellular content of GSH, whose involvement in the antioxidant defense system has already been mentioned ([@B177]). Bax deficiency completely prevented RGC death in DBA/2J mice because the RGC death pathway is Bax-dependent, whereas the axonal degeneration pathway is Bax-independent. Additionally, Bax deficiency delays IOP elevation in glaucoma ([@B155]). Furthermore, activation of caspases 3, 6, 7, and 9 may be endogenously counteracted by inhibitor of apoptosis proteins (IAPs) ([@B149]; [@B85]). It is suggested that members of the IAP family (IAP~1~ and XIAP) may represent endogenous neuroprotective mechanisms that are activated in the retina in response to elevated IOP. Expression of IAPs decreases in glaucomatous retinas and correlates with age, suggesting that an impairment in the IAP system increases the retina's vulnerability to elevated IOP ([@B152]). It is worth mentioning that an siRNA against caspase 2 mRNA, QPI-1007 (Quark Pharmaceuticals) received orphan designation by FDA for optic neuropathy and it is currently under evaluation in phase II clinical trial for glaucoma (NCT01965106) (Figure [3](#F3){ref-type="fig"}).

RNA-Binding Protein HuR
-----------------------

The expression of defense genes can also be modulated by post-transcriptional mechanisms, such as RNA-binding proteins -- RBPs -- and microRNAs, which allow punctual, rapid and localized changes in gene product levels. This control of gene expression is particularly relevant in neurons, whose projections can extend for long distances from the nucleus. A derangement in these mechanisms may thus seriously endanger the physiological cellular response to changing external conditions, representing a critical point of failure in endogenous neuroprotection. Changes in RBPs have been associated with various neurodegenerative diseases ([@B198]; [@B56]); in particular, the RBP HuR/ELAVL1 regulates the expression of hundreds of genes, including stress response proteins (such as SOD1, p53, Hsp70) ([@B172]; [@B14]; [@B173]) and pro- and anti-inflammatory factors ([@B179]), playing a key role in cell survival/apoptosis under stress conditions ([@B144]). Under endogenous or external stimuli (growth factors, inflammatory stimuli, hypoxia, oxidative stress and many others), HuR protein is activated and moves from the nucleus to the cytoplasm, where it favors the stability and/or translation of target RNAs ([@B1]; [@B60]; [@B287]). Lately, the involvement of HuR in mechanisms underlying ocular pathologies has received increasing interest ([@B10], [@B13], [@B12]; [@B127]; [@B253]). Relevant for our context, *in vitro* studies showed that HuR was activated by oxidative stress in TM cells ([@B175]). More recently, *in vivo* evidence by our group revealed that changes in HuR subcellular localization (i.e., nuclear-cytoplasmic shuttling) within RGCs occurred at early times after IOP induction in an animal model of glaucoma; these effects were followed at longer times by a progressive decrease of cytoplasmic HuR levels, including the expression of proteins essential for cell homeostasis (p53, Hsp70) and likely contributes to chronic IOP-induced RGC degeneration ([@B234]). Similar alterations in HuR content and subcellular localization were found in human POAG samples, in support of the involvement of HuR in glaucoma ([@B234]). A relevant role of HuR in neuroprotection was also described in brain neurons ([@B233]). The potential of HuR as a new pharmacological target is shown by an increasing interest in medicinal chemistry by the field (for a review, see [@B182]). There is also some evidence of altered microRNA expression in the AH of glaucoma patients ([@B120]); however, the role of microRNAs, as well as of RBPs and, more generally, of post-transcriptional mechanisms controlling gene expression in glaucoma, needs to be further explored.

Metallothioneins
----------------

Metallothioneins I-IV (MT I-IV) are a family of four metalloproteins that have multiple activities, such as antioxidant (ROS scavenging), regulation of metal homeostasis (mostly Zn, potential heavy metals scavenger), and transcription factors synthesis (MT are a source of Zn for enzymes). MT I, II and III have been documented to have a pivotal role in stress response in neurons ([@B239]; [@B201]). In healthy retinas MT I/II and III are expressed mostly in RGC axons (retinal nerve fiber layer) and the inner plexiform layer ([@B239]). Similarly, isoforms MT I and III have been detected in proteomic analyses of ON homogenates ([@B234]). In stress conditions, expression of MT has been shown to increase within RNFL and RGC bodies, suggesting its role as an endogenous neuroprotective factor ([@B239]). Beside their scavenging properties MT play an important antiapoptotic role (through inhibition of p53, caspase 1, 3, 9 and cytochrome c leakage) and anti-inflammatory activity (by decreasing expression of proinflammatory cytokines, and inhibiting macrophages differentiation). Finally, MT have a strong impact on neuroregeneration and axonal regrowth via the megalin (LRP2) receptor, by increasing the expression of growth factors (NGF, BDNF, GDNF, NT, VEGF) in CNS ([@B201]). This phenomenon was also found and confirmed in RGCs ([@B74]).

Tumor Necrosis Factor Alpha (TNFα) and Neuroinflammation
--------------------------------------------------------

Neuroinflammation is one of the processes involved in the neurodegeneration, also in the retina and the optic nerve ([@B236]; [@B264]). TNFα is considered the critical regulator of neuroinflammation both in the retina and optic nerve, which together with its target receptors TNFR1 and TNFR2 may regulate homeostasis as well as pathophysiological processes. The involvement of TNFα gene and protein alteration in retina has been reported in animal model of glaucoma and human primary open angle glaucoma ([@B274]; [@B268]; [@B265]). In retina and optic nerve, TNFα is rapidly release from glial cells (i.e., microglia, Müller cells) as a response to cell-stress inducing factors, like increased intraocular pressure ([@B51]). It has been shown that soluble TNFα fraction is responsible for detrimental pro-inflammatory and pro-degenerative effects in RGCs and is related to binding with TNFR1, while stimulation of TNFR2 can exhibit protective effects ([@B51]). The molecular pathways of the TNFα-depended neurodegeneration relay on increasing of Ca^2+^ permeability of AMPA receptor (AMPAR) and accumulation of Ca^2+^ in cytosol, mitochondrial damage and ROS production ([@B15]; [@B50]). On the other hand, binding of TNFα to TNFR1 can directly mediate apoptotic response via Fas-Associated Death Domain (FADD) and caspase-3/caspase-8 pathways activation ([@B5]). Moreover, TNFα by binding to TNFR2 can also trigger the activation of survival signals through the stimulation of a transcription factor NF-KB, which inhibit apoptosis. Besides TNFα induces another protection mechanism represented by HSPs ([@B246]). From the excitotoxic point of view, overexpression of TNFα favors the activity of excitatory synapses, inhibits uptake of glutamate by astrocytes and increases release of glutamate from microglia, which all leads to overload of extracellular space with this mediator and results in self-perpetuating excitotoxic insult ([@B193]). Despite of growing evidences of involvement of TNFα pathways in RGC degeneration, there is a clear lack of targeted anti-TNFα, neuroprotective therapies. The promising attempts were done using the inhibitors of soluble TNFα fraction, achieving alleviation of RGC damage in ocular hypertension model ([@B51]). Applying of non-selective anti-TNFα agent (etanercept) suppressed microglial activation and provided optic nerve axons neuroprotection in the rat ocular hypertension model ([@B211]). Interestingly, there are several known TNFα cross-interacting pathways, with described neuroprotective factors. ELAVL1/HuR protein regulates the expression of TNFα, as well as other pro- and anti-inflammatory cytokines, like IL-1, IL-6, IL-8, IL-10, participating in cellular homeostasis ([@B234]). TNFα expression is also regulated by erythropoietin, however, the mechanism of this cross-pathway depends on the way of inflammatory process activation ([@B113]). In the inflammation induced by lipopolysaccharide (LPS), the release of TNFα by microglial cells was proved to be controlled by systemic erythropoietin gene delivery ([@B275]). This approach was ineffective in case of neuroinflammation associated with optic neuropathy, where macroglial cells are the major source of TNFα ([@B247]). In the last case, local erythropoietin gene delivery (i.e., intravitreal) seems to be more efficient option ([@B113]). The neuroprotective effects mediated by down-streaming of TNFα and other proinflammatory cytokines was also reported for endocannabinoids and metallothioneins ([@B110]; [@B142]).

Erythropoietin and Erythropoietin Receptor
------------------------------------------

Erythropoietin (EPO) is a hematopoietic cytokine known as a stimulant of erythropoiesis in response to hypoxia ([@B66]; [@B228]). However, more recently, in addition to bone marrow, the receptor for EPO (EPO-R) has been identified in multiple tissues, including the retina and, more specifically, in RGCs ([@B26]; [@B225]). Stimulation of neuronal EPO-R plays an important role in response to stress and injury and prevents neuronal apoptosis by alleviation of effects of hypoxia, glutamate excitotoxicity and growth-factors deprivation ([@B128]). In their study, [@B128] proved the existence of an endogenous neuroprotective system consisting of EPO/EPO-R that participates in stress response in retinal ischemia/reperfusion. [@B82] studied specific localization of endogenous EPO/EPO-R expression and demonstrated that in healthy conditions, endogenous EPO is expressed among others in the RNFL (RGC axons) and EPO-R in RGC bodies; the expression of both the cytokine and the receptor increases in the rat retina following a glaucoma-mimicking injury. In a DR model, it has been suggested that the molecular basis of EPO activity in RGC is related to its antioxidant action -- by increasing the activities of SOD, GSH-Px, and CAT and by preventing the generation of pro-apoptotic signals what improves RGC survival ([@B256]). Protective EPO activity has also been demonstrated in other models of RGC death, i.e., NMDA excitotoxicity, neurotrophic factors deprivation, inflammatory insults, ON crush and glaucoma ([@B283], [@B285]; [@B213]; [@B41]). In RGC axotomy, EPO-mediated neuroprotection can be related to extracellular signal-regulated kinases ([@B134]). Beside neuroprotection, stimulation of EPO-R can also induce axonal regeneration within RGCs by upregulating growth associated protein-43 and downregulating RhoA and ROCK ([@B243],[@B244]). It is worth remembering that RhoA/ROCK signaling modulates AH outflow; ROCK inhibitors lower intraocular pressure (IOP) via a direct effect on TM and Schlemm's canal, and they are currently under clinical evaluation in glaucoma ([@B257]). Interestingly, it has been reported that topical administration of a ROCK inhibitor promotes RGC survival and axon regeneration after ON injury *in vivo* ([@B226]), suggesting that the beneficial effects of this class of inhibitors may go beyond their action on IOP.

The role of EPO in the eye, its potential for treatment of ocular disorders, and some clinical trials on EPO and EPO derivatives in various ocular disorders other than glaucoma, have been reviewed by [@B229]. However, to our knowledge, there are no ongoing clinical trials of EPO therapy for glaucoma.

Endocannabinoids
----------------

Endocannabinoids (eCBs, i.e., anandamide and 2-arachidonoylglycerol) are physiological ligands for the cannabinoid receptors CB1 and CB2. They represent arachidonate-based retrograde neurotransmitters playing a relevant role in a variety of physiological processes in the central and peripheral nervous systems, including neuroprotection and synaptic plasticity ([@B270]). In the eye, beside the effect of lowering the intraocular pressure (i.e., anandamide), the eCBs system in RGCs modulates neurotransmitter release, enhances processing and integration of visual signals by interacting with the TRPV1 channel and Ca^2+^ and K^+^ ion channels ([@B199]; [@B38]; [@B174]; [@B124]). Nucci et al. proved that the rat retina has a complete and functional endocannabinoid system involving synthesis, transport, hydrolysis and binding of anandamide ([@B189]; [@B223]). Moreover, a decrease of anandamide in retinal ischemia may be involved in RGC loss ([@B189]). Although both CB1 and CB2 receptors are present in the retina, the neuroprotective activity of eCBs has been investigated in various models of RGC pathology and seems to be related to CB1 receptor ([@B140]). In I/R and excitotoxic models of retinal degeneration, stimulation of the CB1 receptor provided neuroprotective effects in different retinal neuron populations ([@B140]). The effect was related to reduction of excitotoxic insult via modulation of glutamate release and activation of antiapoptotic pathways involving PI3K/Akt and MEK/ERK1/2 ([@B258]; [@B94]; [@B132]; [@B176]; [@B194]). In a glaucoma model, activation of CB1 and TRPV1 receptors by the agonist methanandamide, provided RGC neuroprotection and created a possible new target for glaucoma therapy ([@B189]). In the streptozotocin-induced DR model, CB treatment provided better preservation of the blood-retina barrier and anti-inflammatory effects of downstream proinflammatory cytokines, i.e., TNFα ([@B64]).

Neuroglobin
-----------

Neuroglobin (Ngb) is an oxygen-binding heme protein containing iron, represents the neuronal counterpart of blood hemoglobin. Ngb plays a crucial role in endogenous neuroprotection in CNS and RGCs ([@B277]). Ngb can reversibly bind oxygen; thus, it is associated with mitochondrial metabolism and the respiratory chain; Ngb can also supply oxygen to neurons ([@B145]). Due to its high oxygen affinity, Ngb can scavenge ROS, modulating NO-related processes and inducing stress-response in cells due to hypoxia ([@B259]). In RGC pathology, i.e., retinal ischemia and glaucoma, Ngb participates in the stress-response by having an impact on RGC integrity and survival by preventing mitochondrial protein damage and energy failure due to respiratory chain impairment ([@B259]; [@B52]). RGC degeneration may be linked with decreased Ngb content, and supplementation with exogenous Ngb is shown to alleviate RGC death and even to induce axonal outgrowth after ON crush ([@B240]). In DBA2J mice, where glaucomatous-like ON pathology is directly linked with failure of mitochondrial bioenergetics and decreased Ngb content, exogenous delivery of Ngb can slow down progression of RGC degeneration or even reverse it, which brings up a promising application in mitochondrial ON diseases, i.e., LHON ([@B52]).

Estrogens and Their Receptors
-----------------------------

Estrogens are steroid hormones primarily related to the reproductive, skeletal and cardiovascular systems ([@B178]). Estrogen receptors α and β (ER α and β) are expressed within the ocular elements, including the retina, and especially in RGCs ([@B178]). The function of estrogen signaling has been proven to be related to cataractogenesis, dry eye syndrome and AMD ([@B101]). Recent studies also showed involvement of ER β receptors in the endogenous neuroprotection of axotomized RGCs via activation of the ERK-c-Fos pathway ([@B181]), in glaucomatous neurodegeneration via Akt/CREB/thioredoxin-1, MAPK/NF-kappaB and inhibition of IL-18 ([@B286]; [@B215]; [@B205]). In ischemic optic neuropathy, estrogens prevent RGC degeneration if applied before the insult, with no effects of treatment post-insult ([@B31]). Estrogens can prevent the effects of oxidative insult in retinal neurons by activation of PI3K/Akt signaling and exert mitochondrial protection associated with the attenuation of the proapoptotic Bax gene ([@B153]; [@B105]). There is evidence that topical delivery of 17β-estradiol can prevent RGC death in a glaucoma model in rats ([@B205]). In another study, [@B251] showed that estrogen deficiency associated with aging, accelerated optic nerve dysfunction. There is also clinical evidence that postmenopausal estrogen supplementation in women can significantly reduce the risk of POAG development ([@B185]) and that ER2 receptor polymorphism can be associated with increased risk of POAG in men ([@B57]).

Autophagy -- Neuroprotective Aspects
------------------------------------

Autophagy is a cellular clearing system for scavenging misfolded proteins, lipids and other cell components; it prevents protein aggregation and maintains proper organelle turnover, thus assuring cell survival. Autophagy prevents dysfunction of cellular components which may appear due to oxidative insults and increased mitochondrial membrane permeability ([@B55]). In RGCs, the autophagy process has been studied in ocular hypertension models, retinal and ON ischemia, and transection or ON crush ([@B157]). In glaucoma, opposite changes in the autophagy process can be observed in RGCs when compared to the ON; in particular, an increase in autophagy is observed in the cell soma/RGC, and autophagy is impaired in the axons/optic nerve ([@B58]; [@B137]). The significance of this process in RGC biology has not been fully determined yet, and at present it is still unclear whether induction or inhibition leads to beneficial outcomes ([@B197]; [@B238]; [@B138]). Accordingly to this, the effects of autophagy activation may also depend on the cellular compartment in which it takes place; i.e., in glaucoma, autophagy may be initially activated in RGC dendrites and axons, which possibly has protective outcomes, but under the chronic increase of intraocular pressure, autophagosomes appear in the cytoplasm of the cell body, mediating cell death ([@B157]). Interestingly, some of the abovementioned factors have been related to autophagy, suggesting it plays an important role in maintaining RGC homeostasis.

Endoplasmic Reticulum Stress Modulation
---------------------------------------

Different damaging factors may affect intracellular pathways by impairing correct proteins turnover, resulting in accumulation of unfolded and misfolded proteins in the lumen of endoplasmic reticulum (ER). The cell-stress response to this event, known as the unfolded protein response (UPR) activates cascade of reactions and pathways leading to cell death by apoptosis ([@B269]). Recently, the UPR has been postulated to be involved in the pathogenesis of neurodegenerative disorders, including RGCs neurodegeneration such as glaucoma. In animal model of optic neuropathy (traumatic injury and chronic glaucomatous neurodegeneration) it has been shown that inhibition of the protein kinase RNA-like endoplasmic reticulum kinase (PERK)-eukaryotic initiation factor 2 alpha (eIF2α)-CCAAT/enhancer-binding protein homologous protein (CHOP) pathway and activation of the X-box binding protein 1 (XBP-1) pathway play neuroprotective role in RGCs by preventing ER stress-induced protein misfolding, increasing expression of anti-apoptotic Bcl-2 gene and regulating homeostasis of Ca^2+^ ions in ER ([@B115]; [@B273]). [@B192] additionally presented that in DBA/2J mice, ER stress may participate in optic nerve astrocytes activation, overlapping the direct involvement in axonopathy. Targeting the ER stress pathways by gene therapy approach is considered as a novel and promising direction in neuroprotective strategies.

Adenosine and Adenosine Receptors
---------------------------------

Adenosine is derived from ATP and AMP in the cells and can be transported extracellularly by the nucleoside transporters. It plays role in the regulation of the blood flow, inflammatory cytokine release by T-cells, synaptic function, neuromediators release and Ca^2+^ levels in CNS, as well as in neuroprotection ([@B227]). Adenosine receptors (AR) represent class of four known G protein-coupled receptors distributed within different tissues including ocular structures. AR~1~ and AR~3~ receptors stimulation inhibits adenylyl cyclase and decrease cyclic adenosine monophosphate (cAMP) synthesis, while AR~2A~ and AR~2B~ receptors agonists cause activation of adenylyl cyclase and increase cAMP in the cells ([@B78]; [@B227]). In the aspect of glaucoma, stimulation of certain subtypes of AR (i.e., agonists of AR~1~ and AR~3,~ and antagonists of AR~2A~) are expected to have beneficial effects on intraocular pressure reduction or directly on RGC neuroprotection ([@B284]; [@B180]). The neuroprotective aspects of adenosine are related mostly to AR~1~ and AR~3~ receptors. The molecular neuroprotective effects of AR~1~/AR~3~ agonists are explained by anti-apoptotic effect involving deregulation of PKB/NF-κB and Wnt signaling pathways, downregulation of the Fas receptor, and TNFα expressions ([@B73]). Additionally, it has been demonstrated that adenosine signaling (AR~1~ and AR~3~) alleviates excitotoxic insult outcomes by decreasing Ca^2+^ influx, mitochondrial damage and apoptosis related to NMDA or P2X7 receptor stimulation and glutamate accumulation ([@B107]; [@B281], [@B280]). In the study conducted on *in vitro* RGC culture and rat optic nerve crush model, stimulation of AR~3~ promoted RGC neurites outgrowth which proves that agonists of this receptor may exhibit neuroregenerative activity ([@B180]). Interestingly, agonists of AR~2B~ promotes axons elongation in peripheral neurons, what was demonstrated in corneal nerve plexus in diabetic rats ([@B282]).

Concluding Remarks
==================

There are many candidate molecules and pathways identified as potential therapeutic factors for RGCs rescue. It would be a real challenge to judge and justify which of these represent the most potent one, since it is highly probable that revealed effect depends on the pathomechanism of cell damage. Moreover it is possible that combined therapies might be more effective than single factor application, what was observed, for example in neurotrophic factors therapy ([@B186]; [@B262]). It is important to note that majority of described molecules were tested in animal settings therefore anatomical, physiological and functional differences with human retinas may be associated with the discrepancies between the clinical trials conclusions and animal studies outcomes (i.e., memantine trial in glaucoma ([@B266]; [@B261]). From among the factors we described in this review, the human antigen R (HuR protein) seems to be the most promising endogenous target for experimental and translational therapy. In glaucoma, it has been shown that there are similar patterns of HuR protein alterations in both rat and human what allows to expect that effects of HuR-targeted therapies may have similar, thus translational outcomes ([@B234]). HuR protein represent the pleiotropic factor that post-translationally regulates majority of described intracellular processes and molecules, especially antioxidant enzymes, growth factors, stress response factors, cell cycle regulating proteins and autophagy. By modulating single factor -- HuR protein expression and function, it is possible to affect whole cell stress-response mechanisms. It seems to be possible HuR protein is a key element managing these complex mechanisms that determine whether cells survive and remain fully functional.
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